n.a. (ELN)

0.00
NYSE
Prev Close 0.00
Day Low/High 0.00 / 0.00
52 Wk Low/High 0.00 / 0.00
Exchange NYSE
Div & Yield N.A. (N.A)
Elan Does Right by Its Shareholders

Elan Does Right by Its Shareholders

With Johnson & Johnson deal, Elan's on much better financial footing -- even if bapineuzumab's a bust.

No Fireworks In the Market

No Fireworks In the Market

Debra Borchardt and Liz Trotta break down today's market. Guests include Adam Feurestein and Jonathon Corpina.

Top Takes From RealMoney

Top Takes From RealMoney

Here's what some of our market pros are saying and playing.

Dividend.com: Midday Update

Dividend.com: Midday Update

Downgrades, transports and financials are leading the market down.

Cramer's Take on Headline Stocks

Cramer's Take on Headline Stocks

Here's what Jim Cramer's had to say lately about some of the stocks in today's news.

Elan Shares Rise on J&J Investment

Elan Shares Rise on J&J Investment

Elan announces a $1.5 billion investment by J&J wherein it will take over Elan's Alzheimer's unit and assume an 18.4% stake in the company.

'Fast Money' Recap: Will Oil Kill the Rally?

'Fast Money' Recap: Will Oil Kill the Rally?

The trading panel debated the impact of lower oil prices on the market.

Biogen Expands MS Profile in Acorda Deal

Biogen Expands MS Profile in Acorda Deal

Biogen received the rights to commercialize Acorda's multiple sclerosis drug outside of the U.S.

Top Takes From RealMoney

Top Takes From RealMoney

Here's what some of our market pros are saying and playing.

Biogen Reports 10th PML Case With Tysabri

Biogen Reports 10th PML Case With Tysabri

Biogen Idec reports that a tenth multiple sclerosis patient being treated with Tysabri was diagnosed with a serious brain infection.

Monday's Headlines: Elan

Monday's Headlines: Elan

Monday's early headlines include Bernard Madoff's sentencing, the head of the White House Council of Economic Advisors turning more positive on the economy, and reports that UBS is close to settling a tax-related dispute with the U.S.

Novartis in Talks For Parts of Elan

Novartis in Talks For Parts of Elan

The Swiss drugmaker is reportedly in talks to talks to buy certain operations from Ireland's Elan.

'Mad Money Lightning Round': Stick With Johnson & Johnson

'Mad Money Lightning Round': Stick With Johnson & Johnson

Cramer has liked this stock all along.

Biotech Calendar: Key Clinical Trial Dates

A quick and dirty guide to upcoming clinical trial dates for drug and biotech companies.

Bristol, Elan Talks Break Down: Report

Bristol, Elan Talks Break Down: Report

Strategic talks were held last month between Irish drugmaker Elan and Bristol-Myers Squibb, but they broke down in the early stages, a report says.

Best in Class: Biogen Idec Clinging to Its Crown

Biogen Idec is the market leader in mulitiple sclerosis treatments, but oral drug rivals are turning up the pressure.

Gilead Sciences Tops Sales, Profit Targets

Gilead Sciences said its first-quarter revenue surged 22% from a year earlier as product sales reached a record high of $1.45 billion.

Biogen Idec: Tysabri Sales Fall Short

Biogen Idec reports a 27% increase in adjusted first-quarter earnings, but sales of its multiple sclerosis drug Tysabri don't meet estimates.

Biogen's Tysabri Data Key for First Quarter

Biogen's expected to report a solid quarter, leaving investors more likely to focus on Tysabri data and M&A news.

Genentech Pulls Raptiva From U.S. Market

Genentech says it is voluntarily withdrawing its psoriasis drug Raptiva from the U.S. market because of safety concerns.

Elan, Wyeth Drop Top Alzheimer's Drug Dose

Elan and Wyeth are eliminating the highest dose of an Alzheimer's drug from two phase III studies after independent safety monitors concluded patients were at risk for developing swelling of the brain.

Biogen Tries to Quell Fears About MS Drug Rivals

Biogen meets with investors to pitch its research pipeline and stifle worries that its leading position in the multiple sclerosis treatment market is vulnerable to competition.

Biotech Confab: Doctors, Investors Weigh In

Notes from the Cowen and Co. Annual Health Care Conference in Boston.

Biotech Stock Mailbag: Geron Fans Gone Wild

Readers write in about Amgen, phase III trial upsets, Xoma and Elan, and Geron investors go wild.

H-P to Create 500 Jobs In Ireland

Hewlett-Packard plans to create 500 jobs in Ireland over the next 12 months as the tech firm boosts its lucrative services business.

Genentech: Roche Needs Us More

Genentech: Roche Needs Us More

Genentech explains to investors and analysts why Roche's hostile tender offer is too low.

Elan to Cut 14% of Workers in Realignment

Elan to Cut 14% of Workers in Realignment

The Irish drugmaker said it plans to postpone biologics manufacturing and will realign the research and development operations within its biopharmaceutical business.

Genentech Studies How Alzheimer's Attacks Brain

Genentech Studies How Alzheimer's Attacks Brain

Researchers know of a protein that seems to play a key role in causing Alzheimer's disease. But why does this protein reside in the brain in the first place?

Elan Swings to Fourth-Quarter Profit

Elan Swings to Fourth-Quarter Profit

Elan reported fourth-quarter profit of $169.5 million, or 36 cents a share, as sales of multiple sclerosis drug Tysabri soared.

Biogen Shares Fall on Weaker Tysabri Sales

Biogen Idec shares are falling after the company reported weaker-than-expected sales of its multiple sclerosis drug Tysabri and cut the drug's long-term sales outlook.